Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02362035 · ClinicalTrials.gov registry record · Phase 1
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
A Phase 1 study, sponsored by Acerta Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 161
- Enrollment target
NCT02362035: Completed Phase 1 study, sponsored by Acerta Pharma.
NCT02362035 is a Phase 1 study that has completed, run by Acerta Pharma. The registered enrollment target is 161 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (168% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02362035, a Phase 1 study, has completed, sponsored by Acerta Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 161 participants
- Enrollment target
Study Summary
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
Primary Outcome
Treatment-emergent AEs were defined as those events that occurred on or after the first dose of study drug, through the treatment phase, and within 30 days following the last dose of study drug.
Interventions
- DRUG Pembrolizumab
- DRUG Acalabrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2015-02-20 |
| Est. Completion | 2025-10-27 |
| Phase | Phase 1 |
What the finished NCT02362035 record still lists
NCT02362035 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (168% higher).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02362035 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02362035 about?
NCT02362035 is a clinical study titled "ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies". This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
What is the current status of trial NCT02362035?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 161 participants. The study started on 2015-02-20. Estimated completion is 2025-10-27.
What interventions are being tested in trial NCT02362035?
The interventions under investigation include: Pembrolizumab (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT02362035?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02362035's enrollment target sits among peer trials
161 340th of 2000 higher than 1,661 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI